Techbio Pioneer Etcembly Signs Deal With DJS Antibodies, Part of AbbVie, to Accelerate Antibody Discovery Pipeline
British techbio innovator Etcembly has signed a collaboration agreement with DJS Antibodies, a part of AbbVie, to accelerate the discovery of novel antibody therapeutics.
Etcembly and University of Surrey Launch Pioneering Study to Unlock Next-Generation Cancer Treatments From Survivors
British techbio innovator Etcembly is teaming up with researchers and clinicians from the University of Surrey to launch a groundbreaking new study that could transform the future of cancer treatment. By analysing the immune cells of cancer survivors, this research is set to reveal untapped targets that could deliver the next generation of immunotherapies.
Etcembly Launches Groundbreaking Research Study Searching for Cancer Cures in Survivors
British techbio innovator Etcembly has launched a groundbreaking new research study aiming to uncover new targets for cancer therapies by analysing the immune cells of cancer survivors.
TechBio Innovator Etcembly Reveals World’s First Generative AI-designed Bispecific T Cell Engager With Picomolar Affinity
British techbio innovator Etcembly is coming out of stealth mode, kickstarting the next generation of immunotherapies with a pipeline of best-in-class T cell receptor (TCR) therapeutics designed using generative AI.
